This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| KCNJ11 | |
|---|---|
| Name | KATP inward-rectifier potassium channel subunit Kir6.2 |
| Organism | Homo sapiens |
| Gene id | 3767 |
| Location | Chromosome 11p15.1 |
| Length | 390 aa |
| Family | Inward-rectifier potassium channels (Kir) |
KCNJ11
KCNJ11 encodes a member of the inward-rectifier potassium channel family, a pore-forming subunit that assembles into ATP-sensitive potassium (KATP) channels in multiple tissues. The protein couples cellular metabolic state to membrane excitability by responding to intracellular adenine nucleotides and interacting with regulatory sulfonylurea receptor subunits, and it has been implicated in disorders ranging from neonatal diabetes to cardiovascular dysfunction. Work on KCNJ11 intersects with molecular genetics, electrophysiology, pharmacology, and clinical endocrinology.
KCNJ11 is expressed in pancreatic islets, cardiac myocytes, skeletal muscle, and neural tissue, where it co-assembles with ABCC8-encoded sulfonylurea receptor subunits to form hetero-octameric KATP channels. Studies linking KCNJ11 to insulin secretion engaged investigators at institutions including the National Institutes of Health, the Wellcome Trust, and academic centers such as Harvard Medical School and University College London. Human geneticists, electrophysiologists, endocrinologists, and pharmacologists have jointly characterized how variants alter channel gating, with translational implications for treatments informed by clinical trials and drug approvals by agencies like the Food and Drug Administration and European Medicines Agency.
The KCNJ11 gene resides at 11p15.1 and encodes a 390–amino acid protein with two transmembrane domains (M1 and M2), a pore (H5) region, and cytoplasmic N- and C-termini that mediate gating and regulatory interactions. High-resolution structural insights derive from cryo-electron microscopy studies by groups at institutions such as the Max Planck Institute, Stanford University, and Columbia University, and from comparative modeling with bacterial Kir channel structures characterized by laboratories including the University of California, Berkeley. The protein contains canonical motifs shared with the Kir family described by researchers at the European Molecular Biology Laboratory and the Whitehead Institute, facilitating inward rectification and ATP sensitivity determined by nucleotide-binding patches and sulfonylurea receptor contact points.
KCNJ11-containing KATP channels couple cellular metabolism to membrane potential, regulating insulin granule exocytosis in pancreatic beta cells studied in cohorts from the Joslin Diabetes Center and Karolinska Institutet. In cardiac electrophysiology investigated at institutions such as Mayo Clinic and Mount Sinai Hospital, these channels modulate action potential duration during ischemia and reperfusion studied in models developed at Oxford University and Duke University. In the central nervous system, groups at Johns Hopkins University and Massachusetts General Hospital have explored roles in neuronal excitability and protection during metabolic stress. Interactions with signaling pathways involving AMP-activated protein kinase and mitochondrial function have been probed by teams at Rockefeller University and Cold Spring Harbor Laboratory.
Pathogenic variants in KCNJ11 cause monogenic diabetes phenotypes including neonatal diabetes mellitus and maturity-onset diabetes of the young type linked to cohorts assembled by the International Diabetes Federation and the Pediatric Endocrine Society. Clinical entities described in landmark case series from University College London and University of Exeter include permanent neonatal diabetes, transient neonatal diabetes, and syndromic forms with neurological features reported by research groups at the University of Cambridge and University of Oxford. Pharmacogenetic work has guided sulfonylurea therapy transitions overseen in multi-center trials at institutions such as the Royal Free Hospital and University of Chicago. KCNJ11 variants have also been evaluated in population studies by the UK Biobank and Framingham Heart Study for associations with type 2 diabetes risk, cardiac arrhythmias explored by the American Heart Association, and neurodevelopmental disorders investigated by the Simons Foundation Autism Research Initiative.
KCNJ11-containing KATP channels are targets of sulfonylureas and meglitinides developed by pharmaceutical companies including Sanofi, Novo Nordisk, and GlaxoSmithKline; clinical protocols from the American Diabetes Association incorporate these agents for KCNJ11-related neonatal diabetes when sulfonylurea sensitivity permits. Basic pharmacology studies from laboratories at Pfizer and Eli Lilly have characterized blocker and opener kinetics, while academic groups at Yale University and Institut Pasteur have identified modulators that discriminate channel subunit composition. Cardiac cardioplegia and ischemic preconditioning research by teams at Columbia University and Cleveland Clinic have explored KATP channel openers such as nicorandil and pinacidil in preclinical and clinical contexts evaluated by regulatory bodies including the European Society of Cardiology.
Disease-causing missense, nonsense, and promoter-region variants in KCNJ11 alter ATP inhibition, open probability, and trafficking; seminal mutation cataloging efforts were led by consortia involving the Wellcome Trust and the Human Genome Project. Functional assays developed at Vanderbilt University and Institut Curie use patch-clamp electrophysiology, heterologous expression in Xenopus laevis oocytes, and mammalian cell systems refined at Cold Spring Harbor Laboratory to correlate genotype with biophysical phenotype. Modifier loci identified through genome-wide association studies by groups at the Broad Institute and deCODE Genetics suggest polygenic contributions to variable expressivity, while epigenetic regulation at 11p15.5 has been examined in imprinting studies conducted by researchers at King's College London.
Animal and cellular models include Kir6.2 knockout and transgenic mice generated at the Max Planck Institute and University of California, San Francisco, zebrafish lines developed at University of Oregon, and human induced pluripotent stem cell-derived beta cells produced by teams at Stanford and University of Tokyo. Landmark experimental findings from laboratories at Rockefeller University and Institut Pasteur demonstrated sulfonylurea-mediated rescue of insulin secretion in KCNJ11 mutation carriers, informing clinical practice guidelines by the International Society for Pediatric and Adolescent Diabetes. Ongoing trials and mechanistic studies at centers including Mount Sinai and Karolinska continue to refine phenotype–genotype correlations and therapeutic strategies.
Category:Human proteins